FCGR2B
Low affinity immunoglobulin gamma Fc region receptor II-b
As of the edition of 20 October 2026, FCGR2B (low affinity immunoglobulin gamma Fc region receptor II-b, UniProt P31994) has 3 drugs tested at it and 5 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31994
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Immune system; Skin and connective tissue; Cancer; Eye; Nervous system
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Obexelimab | Active | Phase 3 | none listed |
| MGD-010 | Stopped | Phase 2 | none listed |
| BI-1607 | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 3 |
| Total on the list | 5 |
The other 3 companies at FCGR2B
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at FCGR2B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.